| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTSF |
| Uniprot No | Q9UBX1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 273-484aa |
| 氨基酸序列 | PEWDWRSKGAVTKVKDQGMCGSCWAFSVTGNVEGQWFLNQGTLLSLSEQELLDCDKMDKACMGGLPSNAYSAIKNLGGLETEDDYSYQGHMQSCNFSAEKAKVYINDSVELSQNEQKLAAWLAKRGPISVAINAFGMQFYRHGISRPLRPLCSPWLIDHAVLLVGYGNRSDVPFWAIKNSWGTDWGEKGYYYLHRGSGACGVNTMASSAVVD |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与CTSF(组织蛋白酶F)重组蛋白相关的文献摘要概括，供参考：
1. **《Recombinant human cathepsin F (CTSF): expression, purification and enzymatic characterization》**
- 作者：Smith J, et al.
- 摘要：该研究通过哺乳动物表达系统成功表达了重组人CTSF蛋白，并验证了其在酸性pH条件下的蛋白酶活性。实验表明，重组CTSF能够有效降解髓鞘碱性蛋白(MBP)，提示其在神经髓鞘降解中的潜在作用。
2. **《Structural insights into the activation mechanism of cathepsin F》**
- 作者：Wang L, et al.
- 摘要：通过X射线晶体学解析了重组CTSF的酶原结构，揭示了其自抑制状态下的构象变化机制。研究发现，CTSF的活性位点被前肽结构域屏蔽，需通过pH或共因子调控激活，为开发特异性抑制剂提供了结构基础。
3. **《CTSF deficiency in a cellular model of neurodegenerative disorders: Rescue by recombinant enzyme replacement》**
- 作者：Chen X, et al.
- 摘要：利用CRISPR技术构建CTSF缺陷型细胞模型，发现溶酶体功能异常导致α-synuclein聚集。通过外源添加重组CTSF蛋白，部分恢复了溶酶体降解能力，表明其在神经退行性疾病治疗中的应用潜力。
4. **《Proteolytic profiling of recombinant CTSF in tumor microenvironment modulation》**
- 作者：Garcia-Ruiz C, et al.
- 摘要：研究评估了重组CTSF对肿瘤细胞外基质(ECM)的降解能力，发现其通过切割纤连蛋白和层粘连蛋白促进肿瘤细胞侵袭。抑制CTSF活性可减少体内转移，提示其作为癌症治疗靶点的可能性。
---
**说明**：以上文献为示例性概括，实际引用需根据具体研究内容检索PubMed或Web of Science等数据库获取真实文献。CTSF重组蛋白的研究多聚焦于酶学机制、结构生物学及疾病模型中的应用。
Cathepsin F (CTSF) is a lysosomal cysteine protease belonging to the papain-like protease family. It plays a critical role in intracellular protein degradation, antigen processing, and immune regulation. Expressed ubiquitously in human tissues, CTSF is synthesized as an inactive proenzyme that undergoes proteolytic cleavage in lysosomes to become catalytically active. Its enzymatic activity is pH-dependent, functioning optimally in the acidic lysosomal environment. CTSF is implicated in diverse physiological processes, including cellular homeostasis, tissue remodeling, and pathogen defense, while dysregulation has been linked to neurodegenerative disorders, cancer metastasis, and autoimmune diseases.
Recombinant CTSF protein is engineered using heterologous expression systems (e.g., mammalian cells, insect cells, or *E. coli*) to produce high-purity, bioactive enzyme for research and therapeutic development. The recombinant form typically retains key structural features, including the propeptide region and catalytic domain, enabling studies on activation mechanisms and substrate specificity. Researchers utilize recombinant CTSF to investigate its role in lysosomal storage disorders like neuronal ceroid lipofuscinosis, where mutations in the *CTSF* gene disrupt protein function. Additionally, it serves as a tool for screening protease inhibitors and studying tumor microenvironment interactions, as CTSF overexpression correlates with enhanced invasiveness in certain cancers. Recent studies also explore its involvement in MHC class II antigen presentation, highlighting its immunological relevance. The availability of recombinant CTSF accelerates mechanistic studies and drug discovery efforts targeting protease-related pathologies.
×
